AdoRx Therapeutics is an Edinburgh-based drug discovery company focused on identifying new cancer therapies through modulation of the adenosine pathway. Founded in 2017 and led by CEO Pete Finan, the company’s lead programs are the design of adenosine receptor antagonists to overcome the immunosuppressive effects of high adenosine levels in the tumour microenvironment. The team includes Dr Clive McCarthy and Dr Roy Pettipher and collectively has discovered and transitioned more than twenty-five investigational drugs into clinical development. AdoRx raised $10m in initial funding to advance its discovery programs. The company will use the proceeds to continue to develop its candidate molecules. The narrative emphasizes drug-discovery efforts against adenosine-mediated immune evasion in cancer.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2018